Compare Smith & Nephew plc (SNN) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Tesla, Inc. — how do they compare? Smith & Nephew plc trades at $27.17 (market cap $11.10B), while Tesla, Inc. trades at $381.55 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 133.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Tesla, Inc. for 88 Days on average.
| SNN | TSLA | |
|---|---|---|
Market Cap | $11.10B | $1.48T |
Volume | 1,051,703 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $37.17 | $489.88 |
52-Week Low | $26.42 | $298.16 |
Typical Hold Time | 120 Days | 88 Days |
Enterprise Value | $14.13B | $1.45T |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Tesla (TSLA) trades at $377.61, down 0.81% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates, while revenue has softened slightly in 2025. Analyst consensus remains positive with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term earnings pressure and high valuations. Investment opportunities lie in AI and robotaxi growth, but risks include intense EV competition, execution on new technologies, and profitability concerns given a P/E of 347.22. The stock's performance hinges on delivering future growth to justify its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
